Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.36 |
| ▸ | UBE2M | P61081 | 7/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156026 | 0.89 | TRPV1 (0.37) | UBE2MDCUN1D1F10 | |
| SCHEMBL6157569 | 0.88 | TP53 (0.38) | TPSAB1TPSD1TPSG1F10 | |
| SCHEMBL6156474 | 0.88 | F10 (0.47) | UBE2MDCUN1D1F10 | |
| SCHEMBL6156664 | 0.85 | TP53 (0.40) | TPSAB1TPSD1TPSG1F10 | |
| SCHEMBL6156015 | 0.85 | F10 (0.49) | F10 | |
| SCHEMBL6157579 | 0.84 | F10 (0.48) | F10 | |
| SCHEMBL5166370 | 0.83 | F10 (0.54) | TPSAB1TPSD1TPSG1F10 | |
| SCHEMBL6156018 | 0.83 | S1PR1 (0.37) | TPSAB1TPSD1TPSG1KLKB1 | |
| SCHEMBL6159517 | 0.82 | F10 (0.37) | TPSAB1TPSD1TPSG1F10 | |
| Hydrochloric Acid SCHEMBL27601426 | 0.82 | F10 (0.53) | TPSAB1TPSD1TPSG1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | claimed |
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1551839-A1 | PROCESS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE | Kyungdong Pharm. Co., Ltd. (KR) | 2005-07-13 | — | — | EP | disclosed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004007497-A1 | PROCESS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE | KYUNGDONG PHARM. CO., LTD. (KR) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | SERPINC1, F11, F12 | TPSAB1 136/4885TPSD1 538/4885TPSG1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.